Gilead Sciences Inc (GILD): John F Milligan , President and CEO of Gilead Sciences Inc sold 112,000 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $86.92 per share for a total value of $9,736,779.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $86.72 per share price.On Jun 3, 2016, Paul Rutherford Carter (EVP Commercial Ops) sold 2,000 shares at $87.02 per share price.Also, On May 4, 2016, John F Milligan (President and CEO) sold 112,000 shares at $87.70 per share price.On Apr 21, 2016, Gregg H Alton (EVP, Corp & Med Affairs) sold 40,000 shares at $100.01 per share price.
Shares of Gilead Sciences (GILD) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -0.1 points or -0.11% at $87.5 with 79,23,780 shares getting traded. Post opening the session at $87.54, the shares hit an intraday low of $86.9 and an intraday high of $88.24 and the price vacillated in this range throughout the day. The company has a market cap of $116,534 M and the number of outstanding shares has been calculated to be 1,33,18,21,510 shares. The 52-week high of Gilead Sciences is $123.37 and the 52-week low is $81.28.
On Apr 28, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Jun 14, 2016 as the ex-dividend date and fixed the record date on Jun 16, 2016. The payable date has been fixed on Jun 29, 2016.
Company has been under the radar of several Street Analysts.Gilead Sciences is Initiated by Gabelli & Co to Buy and the brokerage firm has set the Price Target at $109. The Rating was issued on Jun 1, 2016.Gilead Sciences is Downgraded by Maxim Group to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Apr 29, 2016.Gilead Sciences is Reiterated by UBS to Buy while Lowering the Price Target of the company shares to $ 118 from a previous price target of $130 . The Rating was issued on Apr 29, 2016.Gilead Sciences is Reiterated by Leerink Partners to Outperform while Lowering the Price Target of the company shares to $ 127 from a previous price target of $130 . The Rating was issued on Mar 16, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.